Conférence

A new preclinical model to test the response of breast cancer to genomically targeted therapy

Réalisation : 7 novembre 2014 Mise en ligne : 7 novembre 2014
  • document 1 document 2 document 3
  • niveau 1 niveau 2 niveau 3
  • audio 1 audio 2 audio 3
Descriptif

Translational science : how to move from biology to clinical applications

The rapid progress in next generation DNA sequencing technology (NGS) means it is now possible, in principle, to obtain a complete list of the genetic abnormalities in a tumour. In practice, clinicians use NGS to obtain a much shorter list of "actionable" mutations that can be targeted with available drugs or used as prognostic markers. Unfortunately, the mere presence of an actionable mutation does not guarantee a response to the cognate drug, as shown by the SAFIR1 study (André et al 2014). To spare patients unnecessary exposure to experimental drugs, we need to prove that their tumours are addicted to the oncogenes we are trying to target. In practice, this means validating proposed treatments on patient-derived xenografts (PDX) before treating patients. This explains the resurgence in interest in PDXs, but the low take rate and slow growth rate of hormone receptor-positive (ER+) breast tumours make it difficult to obtain drug response data in a clinically meaningful timeframe, if at all. Injection of tumour cells into the mammary ducts is a new approach to xenografting developed by Dan Medina's lab to study ductal carcinoma in situ (DCIS). DCIS is notoriously difficult to graft, but Medina and colleagues reported a success rate of nearly 80% with ER+ DCIS. What this tells us is that the mammary ducts create a special microenvironment that provides ideal conditions for the survival and growth of ER+ DCIS cells. We have used intraductal injection to study preneoplastic and invasive breast cancer cells. By injecting genetically engineered preneoplastic human cells into the ducts through the nipple we can completely replace the murine luminal layer with a morphologically normal layer of human luminal cells, a technique we call "humanisation" of the mouse mammary ductal tree (Verbeke et al, submitted). We are now developing protocols to measure the therapeutic response of human patient-derived breast cancer xenografts, with the goal of providing feedback to clinicians within 8 weeks of taking biopsies. We see the combination of NGS and PDX in the neoadjuvant setting as a possible solution to the problem of identifying and killing lethal clones in heterogeneous breast tumours.

Cette présentation a été donnée dans le cadre du ScientificBRIO Day 2 organisé annuellement par le SIRIC BRIO et qui a pour but de réunirtous les acteurs du SIRIC BRIO et plus largement de la cancérologie à Bordeaux.

Intervenants
Thèmes
Notice
Langue :
Anglais
Crédits
Université de Bordeaux - Service Audiovisuel et Multimédia (Production), Université de Bordeaux - Service Audiovisuel et Multimédia (Publication), Université de Bordeaux - Service Audiovisuel et Multimédia (Réalisation)
Conditions d'utilisation
Creative Commons (BY NC)
Citer cette ressource:
Univ Bordeaux. (2014, 7 novembre). A new preclinical model to test the response of breast cancer to genomically targeted therapy. [Vidéo]. Canal-U. https://www.canal-u.tv/75307. (Consultée le 4 juillet 2022)
Contacter

Dans la même collection

  • BRIO support to scientists
    Conférence
    00:13:28
    BRIO support to scientists
    Dessis
    Damien

    BRIO management team was voluntarily built upon various competencies from different horizons (industry, charity…) to provide a broad skillset which aims at supporting the Bordeaux cancer research

  • Multisarc
    Conférence
    00:13:08
    Multisarc
    Italiano
    Antoine

    Translational science : how to move from biology to clinical applications Soft-tissues sarcomas represent an heterogeneous group of tumors. Stadard of care is surgical resection followed by

  • Bordeaux Cancer Initiative
    Conférence
    00:16:54
    Bordeaux Cancer Initiative
    Dessis
    Damien
    Elustondo
    Frédéric

    Translational science : how to move from biology to clinical applications Upon request of the University, the SIRIC was mandated to develop a transversal cancer axis at the University. The axis

  • Curing leukemia ?
    Conférence
    00:19:52
    Curing leukemia ?
    Mahon
    François-Xavier

    Non-pharmaceutical medical innovations and public health The use of tyrosine kinase inhibitors (TKIs) targeted against the BCR-ABL1 oncoprotein has proven remarkably successful in chronic myeloid

  • Standardizing G8 evaluation
    Conférence
    00:15:00
    Standardizing G8 evaluation
    Soubeyran
    Pierre

    Non-pharmaceutical innovations and public health Management of the frail elderly with cancer is a challenge. Beside a poor outcome as compared to younger subjects, physicians will face increased

  • Innovation reimbursement
    Conférence
    00:09:10
    Innovation reimbursement
    Fillatreau
    Christian

    Interface technology/clinical/SHS/public health : case study interventional radiology Novel diagnostic and therapeutic strategies is a continuum of 3 strongly associated phases : clinical

  • Technique, research and benefits
    Conférence
    00:22:10
    Technique, research and benefits
    Grenier
    Nicolas
    Palussière
    Jean

    Interface technology/clinical/SHS/public health : case study interventional radiology   >> Jean Palussière Radiology in oncology or so called interventional oncology is now considered by certain

Sur le même thème